Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates

Bioconjugate Chemistry

Volumn 21, Issue 1, 2010, Pages 84-92

  Erickson, Hans K ^a   Widdison, Wayne C ^a   Mayo, Michele F ^a   Whiteman, Kathleen ^a   Audette, Charlene ^a   Wilhelm, Sharon D ^a   Singh, Rajeeva ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAYTANSINE; MAYTANSINOID DERIVATIVE; PEPTIDE DERIVATIVE; SULFIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISULFIDE BOND; DRUG CONJUGATION; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIPOPHILICITY; MOUSE; NONHUMAN; TUMOR LOCALIZATION;

EID: 74949139946     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc900315y     Document Type: Article

References (27)

1. Bross, P. F., Beitz, J., Chen, G., Chen, X. H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., and Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-6.
2. Wu, A. M., and Senter, P. D. (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-46.
3. Lambert, J. M. (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. 5, 543-9.
4. Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V., Lutz, R. J., Wong, W. L., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D., and Sliwkowski, M. X. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-90.
5. Younes, A., Forero-Torres, A., Bartlett, N. L., Leonard, J. P, Lynch, C., Kennedy, D. A., and Sievers, E. L. (2008) Multiple complete responses in a Phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood (ASH Annual Meeting Abstracts 112, 1006. 2008) in ASH.
6. Xie, H., Audette, C., Hoffee, M., Lambert, J. M., and Blattler, W. A. (2004) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J. Pharmacol. Exp. Ther. 308, 1073-82.
7. Chari, R. V. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41, 98-107.
8. Doronina, S. O., Bovee, T. D., Meyer, D. W., Miyamoto, J. B., Anderson, M. E., Morris-Tilden, C. A., and Senter, P. D. (2008) Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjugate Chem. 19, 1960-3.
9. Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., and Bernstein, I. (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjugate Chem. 13, 40-6.
10. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., and Blattler, W. A. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426-33.
11. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., Wahl, A. F., and Senter, P. D. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjugate Chem. 17, 114-24.
12. Widdison, W. C., Wilhelm, S. D., Cavanagh, E. E., Whiteman, K. R., Leece, B. A., Kovtun, Y., Goldmacher, V. S., Xie, H., Steeves, R. M., Lutz, R. J., Zhao, R., Wang, L., Blattler, W. A., and Chari, R. V. (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 49, 4392-408.
13. Stephan, J. P., Chan, P., Lee, C., Nelson, C., Elliott, J. M., Bechtel, C., Raab, H., Xie, D., Akutagawa, J., Baudys, J., Saad, O., Prabhu, S., Wong, W. L., Vandlen, R., Jacobson, F., and Ebens, A. (2008) Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjugate Chem. 19, 1673-83.
14. Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blattler, W. A., and Goldmacher, V. S. (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66, 3214-21.
15. Chen, Q., Millar, H. J., McCabe, F. L., Manning, C. D., Steeves, R., Lai, K., Kellogg, B., Lutz, R. J., Trikha, M., Nakada, M. T., and Anderson, G. M. (2007) Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin. Cancer Res. 13, 3689-95.
16. Al-Katib, A. M., Aboukameel, A., Mohammad, R., Bissery, M. C., and Zuany-Amorim, C. (2009) Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin. Cancer Res. 15, 4038-45.
17. Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., Perrone, G., Tai, Y. T., Cirstea, D., Raje, N. S., Uherek, C., Dalken, B., Aigner, S., Osterroth, F., Munshi, N., Richardson, P., and Anderson, K. C. (2009) The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15, 4028-37.
18. Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., Frantz, G., Fuji, R. N., Gray, A., Harden, K., Ingle, G. S., Kljavin, N. M., Koeppen, H., Nelson, C., Prabhu, S., Raab, H., Ross, S., Stephan, J. P., Scales, S. J., Spencer, S. D., Vandlen, R., Wranik, B., Yu, S. F., Zheng, B., and Ebens, A. (2009) Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 69, 2358-64.
19. Asai, M. N., K.; and Izawa, M. Demethyl Maytansinoids, U.S. Patent 4,307,016, December 22, 1981.
20. Sawada, T., Kato, Y., Kobayashi, H., Hashimoto, Y., Watanabe, T., Sugiyama, Y., and Iwasaki, S. (1993) A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin. Bioconjugate Chem. 4, 284-9.
21. Bissery, M. C., Guenard, D., Gueritte-Voegelein, F., and Lavelle, F. (1991) Experimental antitumor activity of taxotere
22. (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 51, 4845-52.
23. Gupta, R. S. (1985) Species-specific differences in toxicity of antimitotic agents toward cultured mammalian cells. J. Natl. Cancer Inst. 74, 159-64.
24. Lyng, H., Haraldseth, O., and Rofstad, E. K. (2000) Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn. Reson. Med. 43, 828-36.
25. Jain, R. K. (1999) Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1, 241-63.
26. Thurber, G. M., Schmidt, M. M., and Wittrup, K. D. (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Delivery Rev. 60, 1421-34.
27. Beckman, R. A., Weiner, L. M., and Davis, H. M. (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-9.